ReS-19T is under clinical development by ReMYND and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ReS-19T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ReS-19T overview

ReS-19T is under development for the treatment of Alzheimer's disease (AD). The therapeutic candidate is a small molecule. It acts by targeting tau protein. The program carries the aim to decelerate or even stop cellular degeneration in protein misfolding disorders, such as Alzheimer's. It is administered through oral route.

ReMYND overview

reMYND is a clinical-stage company that develops disease-modifying treatments caused by cellular dysfunction. The company’s pipeline programs include ReS19-T, ReS9-S ReS3-T and ReS18-H. Its pipeline candidates treat alzheimer’s, epilepsy, parkinson’s and huntington’s disease. reMYND also provides contract research services to its clients to assess the pharmacokinetics, pharmacodynamics and efficacy of experimental treatments in its proprietary animal models. The company’s CRO technology platform concentrates on protein-misfolding disorders such as Huntington’s disease and amyotrophic lateral sclerosis to discover and develop drug candidates. reMYND is headquartered in Leuven, Brabant Flamand, Belgium.

For a complete picture of ReS-19T’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.